Abstract Background: Only lamivudine has been included for patients with chronic hepatitis B (CHB) in the National List of Essential Drugs (NLED), a pharmaceutical reimbursement list in Thailand. There have also been no economic evaluation studies of CHB drug treatments conducted in Thailand yet. I

Boonying Siribumrungwong1, Pinit Noorit2, Chumpon Wilasrusmee3, Pattara Leelahavarong4, Ammarin Thakkinstian5 and Yot Teerawattananon4 Abstract Objectives: To conduct economic evaluations of radiofrequency ablation, ultrasound-guided foam sclerotherapy and surgery for great saphenous vein ab

Yot Teerawattananon, Alia Luz* , Songyot Pilasant, Suteenoot Tangsathitkulchai, Sarocha Chootipongchaivat, Nattha Tritasavit, Inthira Yamabhai and Sripen Tantivess Abstract Background: It is very challenging for resource-limited settings to introduce universal health coverage (UHC), particular

Objective: Implementing national-level vaccination programs involves long-term investment, which can be a significant financial burden, particularly in resource-limited settings. Although many studies have assessed the economic impacts of providing vaccinations, evidence on the positive and negative

Abstract BACKGROUND: Pegylated interferon alpha 2a, alpha 2b and ribavirin have been included to the National List of Essential Medicines (NLEM) for treatment of only chronic hepatitis C genotypes 2 and 3 in Thailand. This reimbursement policy has not covered for other genotypes of hepatitis

Sripen Tantivess & Viroj Tangcharoensathien Abstract Thailand achieves universal health coverage through the introduction of 3 benefit schemes: the Civil Servant Medical Benefit Scheme (CSMBS), Social Security Scheme, and Universal Coverage Scheme. The primary benefit package of these sche

Background Economic evaluation has been implemented to inform policy in many areas, including coverage decisions, technology pricing, and the development of clinical practice guidelines. However, there are barriers to evidence-based policy in low- and middle-income countries (LMICs) that include li

Abstract Introduction Cancer has a high mortality rate and morbidity burden in Sri Lanka. This study estimated the economic cost of smoking and smokeless tobacco (ST) related to cancers in Sri Lanka in 2015. Methods Prevalence-based cost of illness is calculated according to the guidelines o

Abstract BACKGROUND: Economic evaluation has been implemented to inform policy in many areas, including coverage decisions, technology pricing, and the development of clinical practice guidelines. However, there are barriers to evidence-based policy in low- and middle-income countries (LMICs) th

Abstract India is at crossroads with a commitment by the government to universal health coverage (UHC), driving efficiency and tackling waste across the public healthcare sector. Health technology assessment (HTA) is an important policy reform that can assist policy-makers to tackle inequities an